Swedish biotech Gabather has received the approval from the Portuguese authorities to go ahead with a target engagement study to complete the phase I evaluation of GT-002, the company’s candidate targeting mood disorders.
As patient recruitment for the study proceeds, BioStock got in touch with CEO Michael-Robin Witt to learn more about the timeline for.